Navigant Study- Treatment Patterns in mCRPC (Metastatic Castrate Resistant Prostate Cancer ) (Navigant)
Current Management, Treatment Patterns and Outcomes of Metastatic Castrate Resistant Prostate Cancer Patients Treated With Radium-223
Sponsor: Bayer
This observational or N/A phase trial investigates Prostatic Neoplasms, Castration-Resistant and is currently completed. Bayer leads this study, which shows 15 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
15 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Apr 2020 — Jan 2021 [monthly]
Completed
-
May 2019 — Apr 2020 [monthly]
Completed
Status: Active Not Recruiting → Completed
▶ Show 10 earlier versions
-
Apr 2019 — May 2019 [monthly]
Active Not Recruiting
-
Mar 2019 — Apr 2019 [monthly]
Active Not Recruiting
-
Feb 2019 — Mar 2019 [monthly]
Active Not Recruiting
-
Jan 2019 — Feb 2019 [monthly]
Active Not Recruiting
Status: Completed → Active Not Recruiting
-
Jun 2018 — Jan 2019 [monthly]
Completed
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
-
Feb 2018 — Apr 2018 [monthly]
Completed NA
Status: Recruiting → Completed
-
Aug 2017 — Feb 2018 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Apr 2017 — Aug 2017 [monthly]
Not Yet Recruiting NA
-
Jan 2017 — Apr 2017 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Bayer
For direct contact, visit the study record on ClinicalTrials.gov .